Annovis Bio (ANVS) News Today $1.70 -0.13 (-6.83%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Annovis Bio-Aktie fällt auf 52-Wochen-Tief von 2,42 US-DollarFebruary 20, 2025 | de.investing.comAnnovis Bio to Host Patient-Centered Webcast on Key Clinical DevelopmentsFebruary 20, 2025 | msn.comAnnovis to Host Patients' Live Forum on February 27, 2025February 19, 2025 | globenewswire.comAnnovis Bio-Aktie fällt auf 52-Wochen-Tief bei 2,59 US-DollarFebruary 11, 2025 | de.investing.comAnnovis Bio stock hits 52-week low at $2.59 amid sharp declineFebruary 11, 2025 | msn.comAnnovis Bio downgraded to Hold from Buy at D. Boral CapitalFebruary 11, 2025 | markets.businessinsider.comD. Boral Capital Downgrades Annovis Bio (ANVS)February 11, 2025 | msn.comAnnovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 7, 2025 | globenewswire.comAnnovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s DiseaseFebruary 6, 2025 | markets.businessinsider.comAnnovis Bio announces first patients entered Phase 3 study of buntanetapFebruary 6, 2025 | markets.businessinsider.comAnnovis Bio (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug DevelopmentFebruary 6, 2025 | theglobeandmail.comAnnovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s ResearchFebruary 6, 2025 | msn.comAnnovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's DiseaseFebruary 5, 2025 | globenewswire.comAnnovis Bio, Inc. Announces Closing of $21 Million Public OfferingFebruary 4, 2025 | financialpost.comAnnovis Bio, Inc. Announces Closing of $21 Million Public OfferingFebruary 4, 2025 | globenewswire.comAnnovis Bio Prices Offering Of 5.25 Mln Shares At $4/Share, Stock Falls In Pre-MarketFebruary 3, 2025 | markets.businessinsider.comAnnovis Bio falls -25.6%February 3, 2025 | markets.businessinsider.comAnnovis Bio stock dips after pricing $21M securities offeringFebruary 3, 2025 | msn.comAnnovis Bio stock hits 52-week low at $4.05 amid market challengesFebruary 3, 2025 | msn.comAnnovis Bio, Inc. Announces Pricing of $21 Million Public OfferingFebruary 3, 2025 | financialpost.comAnnovis Bio announces pricing of $21M offering of stock, warrantsFebruary 3, 2025 | markets.businessinsider.comAnnovis Bio, Inc. Announces Pricing of $21 Million Public OfferingFebruary 3, 2025 | globenewswire.comAnnovis Bio Announces Public Offering of Common Stock and WarrantsFebruary 2, 2025 | msn.comAnnovis Bio, Inc. Announces Proposed Public OfferingJanuary 31, 2025 | financialpost.comAnnovis Bio, Inc. Announces Proposed Public OfferingJanuary 31, 2025 | financialpost.comAnnovis Bio, Inc. Announces Proposed Public OfferingJanuary 31, 2025 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Merit Financial Group LLCMerit Financial Group LLC lifted its stake in shares of Annovis Bio, Inc. (NYSE:ANVS - Free Report) by 269.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,516 shares of the company's stock after buying an additional 71,81January 24, 2025 | marketbeat.comAnnovis Bio Secures U.S. Patent for Neuroprotective Drug BuntanetapJanuary 17, 2025 | msn.comAnnovis Bio granted U.S. patent covering buntanetapJanuary 14, 2025 | markets.businessinsider.comAnnovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global ProtectionJanuary 14, 2025 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Buy" by AnalystsShares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buyJanuary 11, 2025 | marketbeat.comAnnovis Bio: Strategic Advancements and Phase 3 Trial Acceleration Justify Buy RatingJanuary 8, 2025 | markets.businessinsider.comFDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s StudyJanuary 8, 2025 | msn.comAnnovis Bio announces FDA acceptance of protocol for Phase 3 AD studyJanuary 8, 2025 | markets.businessinsider.comFDA genehmigt überarbeitetes Protokoll für Annovis Bios Phase-3-Studie zur Alzheimer-KrankheitJanuary 7, 2025 | de.investing.comFDA genehmigt überarbeitetes Studienprotokoll von Annovis Bio für Alzheimer-StudieJanuary 7, 2025 | de.investing.comAnnovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study ProtocolJanuary 7, 2025 | msn.comFDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development PathwayJanuary 7, 2025 | finance.yahoo.comAnnovis Bio (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’December 30, 2024 | theglobeandmail.comAnnovis Bio (NYSE: ANVS) Committed to Ensuring Highest Standards in Buntanetap TrialsDecember 23, 2024 | theglobeandmail.comAnnovis Bio-Aktie erreicht 52-Wochen-Tief bei 4,52 US-DollarDecember 19, 2024 | de.investing.comShort Interest in Annovis Bio, Inc. (NYSE:ANVS) Declines By 5.8%Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 1,310,000 shares, a decline of 5.8% from the November 15th total of 1,390,000 shares. Based on an average daily trading volume, of 254,500 shares, the days-to-cover ratio is presently 5.1 days.December 17, 2024 | marketbeat.comAnnovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Buy" from AnalystsAnnovis Bio, Inc. (NYSE:ANVS - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strongDecember 17, 2024 | marketbeat.comAnnovis Bio Advances Alzheimer’s and Parkinson’s Drug TrialsDecember 12, 2024 | markets.businessinsider.comAnnovis Bio Appoints William Fricker as Interim CFODecember 10, 2024 | markets.businessinsider.comAnnovis Bio ernennt Interims-CFODecember 9, 2024 | de.investing.comAnnovis Bio (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative DiseasesDecember 5, 2024 | theglobeandmail.comAnnovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s MarketplaceDecember 5, 2024 | finance.yahoo.comAnnovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's MarketplaceDecember 5, 2024 | globenewswire.com/C O R R E C T I O N -- Today's Marketplace/December 4, 2024 | prnewswire.com Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address ANVS Media Mentions By Week ANVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANVS News Sentiment▼1.000.71▲Average Medical News Sentiment ANVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANVS Articles This Week▼14▲ANVS Articles Average Week Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Elutia News Today Ventyx Biosciences News Today Vigil Neuroscience News Today Immunic News Today InflaRx News Today Procaps Group News Today Virios Therapeutics News Today Milestone Pharmaceuticals News Today Atossa Therapeutics News Today Coya Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANVS) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
